4x the Performance, Zero Compromise: How Functionalized Polymers Are Changing the Rules
In the race to decarbonize the global economy, advanced materials are no longer a luxury – they’re a necessity. The global specialty polymer market, valued at over $87 billion globally (2024), is fast becoming the backbone of innovations in clean energy, medical devices, and high-performance electronics.
Forging the Future: Why Strategic Outsourcing in Biologics is No Longer Optional, It’s Essential for Success
The biologics revolution is in full swing, and as innovation accelerates, so does the complexity of bringing these life-changing therapies to market. With the BIO International Convention on the horizon, the corridors will be buzzing with talk of groundbreaking science.
Paws, Pills and Progress – CRDMO’s pivotal role
As I stepped into the conference hall in Boston, I overheard an investor say, “The next billion-dollar biotech might just come from the animal health sector.
SynWeave™: Revolutionizing Biopharma Manufacturing by Improving Titer, Timelines and Manufacturability
Since the establishment of Chinese Hamster Ovary (CHO) cells in the 1950s, the production of therapeutic proteins has seen continuous innovation and growth. The potential of therapeutic proteins, such as antibodies, bispecifics, antibody-drug conjugates (ADCs), and recombinant proteins, is driving the demand for high-titer clones.
Harnessing the Power of Upstream Platform Integration to Accelerate Biopharma Innovation
The biopharmaceutical industry has been a hotbed of innovation in recent years, with an increasing number of novel recombinant protein therapeutics receiving the U.S. Food and Drug Administration’s (FDA) green light.
The Future of Therapeutics: Syngene Leading the Charge with Targeted Protein Degradation Platform
In this exclusive interview Kenneth Barr, SVP of Discovery Research at Syngene International, sheds light on how Syngene is uniquely positioned to lead the targeted protein degradation revolution in drug discovery.
The $100 Billion Frontier: Untapped Potential in Animal Health Innovation
The global animal health market is a staggering $60 billion industry, projected to reach $100 billion by 2030. This phenomenal growth reflects a confluence of factors: rising pet ownership (especially companion animals), increasing protein demand, reducing gaseous emissions, and the ever-present threat of zoonotic diseases.
Advancing mAb manufacturing with customer-centric solutions
Monoclonal antibodies (mAbs) have become a cornerstone in modern therapeutics, offering targeted treatment options across various diseases, including cancer, autoimmune disorders, and infectious diseases.
Selecting the right preclinical species for screening oral dosage form for PK studies
Learn how Syngene helped a pharma client optimize extended-release drug development by identifying the right animal species as a preclinical model. This decision enhanced PK study accuracy, reduced development time, and supported regulatory success for a once-daily epilepsy treatment.
Accelerating development of a unique molecule to treat lung cancer
Learn how Syngene collaborated with a pharma company to develop the drug substance and drug product for a unique molecule to treat locally advanced lung cancer, including optimizing the process to enable commercial manufacturing of the API.